Boston Scientific, a biomedical/biotechnology engineering firm, completed the acquisition of Relievant Medsystems, a medical technology company, for $850m. "The revolutionary therapy from Relievant has tremendous potential to help even more people living with chronic pain. The completion of this acquisition further differentiates our position in advanced interventional chronic pain, offering physicians the broadest selection of evidence-based treatment options that address multiple pain targets and change patients' lives," Jim Cassidy, Boston Scientific, President of Neuromodulation.